Lori S. Friedman - Department of Molecular and Cell Biology and School of Public Health, University of California

基本信息

浏览量：111

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 377 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

62 (PB050): ORIC-114, a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, Demonstrates Best-in-class Properties Against Exon 20 Insertions and Other Atypical EGFR Mutations

M. Junttila, C.E. Repellin, R. Warne, J.E. Long, L. Sambucetti, P. Ashley, G. Andreatta, J. Baik, S. Salaniwal, C. Colas, A. Romero, L. Soroceanu,R. Patel,E. Chow Maneval,P.S. Multani,A. Daemen,L. Friedman

European Journal of Cancer (2024): 114589

引用0浏览0引用

ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor with Best-in-class Properties, Demonstrates Combination Synergy with AR Pathway Inhibitors in Prostate Cancer Models

Anneleen Daemen,Natalie Yuen,Amber Wang,Aleksandr Pankov,Livia Ulicna,Chelsea Chen,Frank L. Duong,Jason Long,Matthew A. Marx,James G. Christensen,Lori S. Friedman,Melissa R. Junttila

Cancer Researchno. 6_Supplement (2024): 6586-6586

引用0浏览0引用

ORIC-613, a Potential First- and Best-in-class, Orally Bioavailable, Potent and Selective PLK4 Inhibitor with Synthetic Lethality in TRIM37 High Cancer Models

Kyle A. Edgar,Siobhan McRee, Gina Andretta,Chelsea Chen,Christophe Colas, Wei Fang,Wayne Kong,Jason Long, Fang Liu,Jared Moore, Aleskandr Pankov, Dan Shore, Joanne Tan,Robert Warne,Livia Ulicna,Rakesh Vekariya,Anneleen Daemen, F. Romero,Melissa R. Junttila,Lori S. Friedman

Cancer Researchno. 6_Supplement (2024): 594-594

引用0浏览0引用

Discovery of ORIC-944, a Novel Inhibitor of PRC2 with Best-in-class Properties for the Treatment of Prostate Cancer

CANCER RESEARCHno. 7 (2024)

引用0浏览0引用

A Novel Small Molecule Inhibitor of CD73 Triggers Immune-Mediated Multiple Myeloma Cell Death

Arghya Ray,Ting Du,Xueping Wan,Yan Song, Sindhu C. Pillai, Md. Abu Musa, Teng Fang,Jared Moore,Brian Blank,Xiaohui Du, Xi Chen,Robert Warne,Dena Sutimantanapi, Fang Lui,Tatiana Zavorotinskaya,Christophe Colas,Lori Friedman,Melissa R. Junttila,Dharminder Chauhan,Kenneth C. Anderson

Blood cancer journal（2024）

引用1浏览0WOSNATURE引用

Abstract ND04: Discovery of ORIC-944, a Novel Inhibitor of PRC2 with Best-in-class Properties for the Treatment of Prostate Cancer

Cancer Researchno. 7_Supplement (2024)

引用0浏览0引用

Preclinical Assessment of the PI3Kα Selective Inhibitor Inavolisib and Prediction of Its Pharmacokinetics and Efficacious Dose in Human

Laurent Salphati,Jodie Pang,Emile G. Plise,Jonathan Cheong,Marie-Gabrielle Braun,Lori S. Friedman, Rebecca Hong Thibodeau,Allan Jaochico, Ryan Johnson,Ning Liu,Michelle Nannini,Deepak Sampath,Kyung Song, Emily J. Hannan,Steven T. Staben

XENOBIOTICA（2024）

引用2浏览0WOS引用

Supplementary Figure Legends 1-8 from Intermittent Administration of MEK Inhibitor GDC-0973 Plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

Klaus P. Hoeflich,Mark Merchant,Christine Orr,Jocelyn Chan,Doug Den Otter,Leanne Berry,Ian Kasman,Hartmut Koeppen, Ken Rice,Nai-Ying Yang,Stefan Engst,Stuart Johnston,Lori S. Friedman,Marcia Belvin

crossref（2023）

引用0浏览0引用

Supplementary Figure 2 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal

Giuseppe Floris,Agnieszka Wozniak,Raf Sciot,Haifu Li,Lori Friedman,Thomas Van Looy,Jasmien Wellens,Peter Vermaelen,Christophe M. Deroose,Jonathan A. Fletcher,Maria Debiec-Rychter,Patrick Schöffski

openalex（2023）

引用0浏览0引用

Supplementary Table S3 from Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Carol O'Brien,Jeffrey J. Wallin,Deepak Sampath, Debraj GuhaThakurta,Heidi Savage,Elizabeth A. Punnoose,Jane Guan,Leanne Berry, Wei,Lukas C. Amler,Marcia Belvin,Lori S. Friedman,Mark R. Lackner

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn